Drugs / QLS31905
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05278832 | Oct 2021 → Dec 2022 | cancer | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06041035 | Oct 2023 → Oct 2024 | cancer | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07151872 | Sep 2025 → Oct 2026 expected | bile duct carcinoma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06942767 | Jun 2025 → Dec 2026 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06446388 | Jun 2024 → Jun 2026 overdue | neoplasm | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07079228 | Sep 2025 → Dec 2028 expected | malignant pancreatic neoplasm | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS31905 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06041035 ↗ |
| Route | Intravenous | “Administered as an intravenous infusion.” NCT06041035 ↗ |
| Target | CLDN18 | “targeting CD3 and CLDN18.2” NCT06942767 ↗ |